Form 4: Syros Pharmaceuticals Director Nancy A. Simonian Reports Stock Transactions

Director Nancy A. Simonian reported the vesting of restricted stock units and subsequent acquisition of Syros Pharmaceuticals common stock on October 31, 2024.

Summary

• On October 31, 2024, Nancy A. Simonian, a director of Syros Pharmaceuticals, Inc., reported a transaction involving the vesting of restricted stock units.
• The transaction involved the vesting of 40,125 restricted stock units, which converted into 40,125 shares of common stock.
• Following the transaction, Simonian directly owns 175,783 shares of Syros Pharmaceuticals common stock.
• The restricted stock units were granted on October 6, 2022, and vested in two equal installments on October 31, 2023, and October 31, 2024.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Positives

• The vesting of restricted stock units and subsequent acquisition of common stock by a director signals confidence in the company's future.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their transactions in the company's stock. It's a common practice for directors and officers to receive stock-based compensation, and the vesting of these awards is a regular occurrence.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding insider activity.

Key Dates

Keywords

Syros Pharmaceuticals, Director, Nancy A. Simonian, Stock Transaction, Restricted Stock Units, Common Stock, Vesting, Ownership